Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Edwards Lifesciences reported its third-quarter 2025 financial results, showcasing a strong performance with a 12.6% year-over-year increase in sales, reaching $1.55 billion.</li><li>This growth was primarily driven by the company's diverse structural heart portfolio, which includes transcatheter aortic valve replacement (TAVR), transcatheter mitral and tricuspid therapies (TMTT), and surgical innovations.</li><li>The results exceeded expectations, prompting Edwards Lifesciences to raise its full-year sales growth guidance to the higher end of its previous range of 9% to 10% and adjusted earnings per share estimate to between $2.56 and $2.62.</li></ul>

Edwards Lifesciences reported its third-quarter 2025 financial results, showcasing a strong performance with a 12.6% year-over-year increase in sales, reaching $1.55 billion.This growth was primarily driven by the company's diverse structural heart portfolio, which includes transcatheter aortic valve replacement (TAVR), transcatheter mitral and tricuspid therapies (TMTT), and surgical innovations.The results exceeded expectations, prompting Edwards Lifesciences to raise its full-year sales growth guidance to the higher end of its previous range of 9% to 10% and adjusted earnings per share estimate to between $2.56 and $2.62.

Edwards Lifesciences Is Focusing On Heart Therapy with EVOQUE & SAPIEN M3 — Will It Pay Off?

<ul><li>Edwards Lifesciences has reported its financial results for the second quarter of 2025, demonstrating a robust performance across various segments.</li><li>The company, which specializes in heart valve technologies and structural heart therapies, showcased a notable double-digit sales growth, driven by the dynamic expansion of its Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) product lines.</li><li>Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.</li></ul>

Edwards Lifesciences has reported its financial results for the second quarter of 2025, demonstrating a robust performance across various segments.The company, which specializes in heart valve technologies and structural heart therapies, showcased a notable double-digit sales growth, driven by the dynamic expansion of its Transcatheter Aortic Valve Replacement (TAVR) and Transcatheter Mitral and Tricuspid Therapies (TMTT) product lines.Baptista Research looks to evaluate the different factors that could influence the company's price in the near future and attempts to carry out an independent valuation of the company using a Discounted Cash Flow (DCF) methodology.

Edwards Lifesciences: Will Its Focus On New & Potentially Game-Changing Heart Therapies Pay Off?

<ul><li>Edwards Lifesciences Corporation reported a solid performance for the first quarter of 2025, with total company sales reaching $1.41 billion, which indicates an 8% growth.</li><li>This growth reflects the company's continued commitment to innovation in the field of structural heart disease, bolstered by its diverse product portfolio.</li><li>The Transcatheter Aortic Valve Replacement (TAVR) segment, with sales of $1.05 billion, experienced growth of 5.4% year-over-year.</li></ul>

Edwards Lifesciences Corporation reported a solid performance for the first quarter of 2025, with total company sales reaching $1.41 billion, which indicates an 8% growth.This growth reflects the company's continued commitment to innovation in the field of structural heart disease, bolstered by its diverse product portfolio.The Transcatheter Aortic Valve Replacement (TAVR) segment, with sales of $1.05 billion, experienced growth of 5.4% year-over-year.

How Edwards Lifesciences Is Breaking Barriers in Valve Replacement with M3 & EVOQUE!

<ul><li>Edwards Lifesciences Corporation recently reported its financial results for the fourth quarter and the full year of 2024, providing an insight into its strategic performance and outlook.</li><li>The company, solely focused on structural heart solutions after divesting its Critical Care segment in the third quarter of 2024, recorded robust financial performance, consistent with its expectations and strategic focus.</li><li>For the full year 2024, Edwards Lifesciences reported a 9% increase in sales, reaching $5.4 billion.</li></ul>

Edwards Lifesciences Corporation recently reported its financial results for the fourth quarter and the full year of 2024, providing an insight into its strategic performance and outlook.The company, solely focused on structural heart solutions after divesting its Critical Care segment in the third quarter of 2024, recorded robust financial performance, consistent with its expectations and strategic focus.For the full year 2024, Edwards Lifesciences reported a 9% increase in sales, reaching $5.4 billion.

Edwards Lifesciences: Inside the High-Stakes Race for the Next Big Cardiac Breakthrough!

Global Healthcare Analyst

Tina Banerjee

<ul>
<li>
<a href="https://www.smartkarma.com/entities/medtronic-plc" target="_blank" data-smartkarma-citation="entities:14982:1" rel="noopener">Medtronic Plc (MDT US)</a> reported Q2FY24 revenue of $8B, representing 5% organic growth, topping guidance of 4.0–4.5%. Cardiovascular, neuroscience, and medical surgical grew mid-single-digit with diabetes accelerating to high-single-digit.</li>
<li>The company now expects FY24 organic revenue growth of 4.75% versus the prior 4.5%. Medtronic raised FY24 adjusted EPS guidance to $5.13–5.19 from $5.08–5.16 earlier.</li>
<li>In November, the company has received FDA approval for innovative renal denervation device for the treatment of hypertension, which should open a multi-billion-dollar market opportunity.</li>
</ul>



Medtronic Plc (MDT US) reported Q2FY24 revenue of $8B, representing 5% organic growth, topping guidance of 4.0–4.5%. Cardiovascular, neuroscience, and medical surgical grew mid-single-digit with diabetes accelerating to high-single-digit.
The company now expects FY24 organic revenue growth of 4.75% versus the prior 4.5%. Medtronic raised FY24 adjusted EPS guidance to $5.13–5.19 from $5.08–5.16 earlier.
In November, the company has received FDA approval for innovative renal denervation device for the treatment of hypertension, which should open a multi-billion-dollar market opportunity.


Medtronic (MDT US): Beat-And-Raise Q2; Weight Loss Drugs Not to Impact Growth; New Device Approval

United States

Edwards Lifesciences Corporation designs, develops, manufactures, and markets products and services to treat late-stage cardiovascular disease.  The Company's products include tissue replacement heart valves, heart valve repair products, hemodynamic monitoring devices, angioscopy equipment, oxygenators, and pharmaceuticals.  Edwards supplies its products to customers located worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Edwards Lifesciences (EW US)

Edwards Lifesciences Is Focusing On Heart Therapy with EVOQUE & SAPIEN M3 — Will It Pay Off?

Edwards Lifesciences reported its third-quarter 2025 financial results, showcasing a strong performance with a 12.6% year-over-year increase in...

Baptista Research

Edwards Lifesciences: Will Its Focus On New & Potentially Game-Changing Heart Therapies Pay Off?

Edwards Lifesciences has reported its financial results for the second quarter of 2025, demonstrating a robust performance across various...

Baptista Research

How Edwards Lifesciences Is Breaking Barriers in Valve Replacement with M3 & EVOQUE!

Edwards Lifesciences Corporation reported a solid performance for the first quarter of 2025, with total company sales reaching $1.41 billion,...

Baptista Research

Edwards Lifesciences: Inside the High-Stakes Race for the Next Big Cardiac Breakthrough!

Edwards Lifesciences Corporation recently reported its financial results for the fourth quarter and the full year of 2024, providing an insight...

Baptista Research

Medtronic (MDT US): Beat-And-Raise Q2; Weight Loss Drugs Not to Impact Growth; New Device Approval

Medtronic reported Q2FY24 organic revenue growth of 5%. The company raised FY24 organic revenue growth and EPS guidance. FDA approval for a new...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Edwards Lifesciences Is Focusing On Heart Therapy with EVOQUE & SAPIEN M3 — Will It Pay Off?

Edwards Lifesciences reported its third-quarter 2025 financial results, showcasing a strong performance with a 12.6% year-over-year increase in...

Baptista Research

Edwards Lifesciences: Will Its Focus On New & Potentially Game-Changing Heart Therapies Pay Off?

Edwards Lifesciences has reported its financial results for the second quarter of 2025, demonstrating a robust performance across various...

Baptista Research

How Edwards Lifesciences Is Breaking Barriers in Valve Replacement with M3 & EVOQUE!

Edwards Lifesciences Corporation reported a solid performance for the first quarter of 2025, with total company sales reaching $1.41 billion,...

Baptista Research

Edwards Lifesciences: Inside the High-Stakes Race for the Next Big Cardiac Breakthrough!

Edwards Lifesciences Corporation recently reported its financial results for the fourth quarter and the full year of 2024, providing an insight...

Baptista Research

Medtronic (MDT US): Beat-And-Raise Q2; Weight Loss Drugs Not to Impact Growth; New Device Approval

​Medtronic reported Q2FY24 organic revenue growth of 5%. The company raised FY24 organic revenue growth and EPS guidance. FDA approval for a new...

Tina Banerjee

Medtronic reported Q2FY24 organic revenue growth of 5%. The company raised FY24 organic revenue growth and EPS guidance. FDA approval for a new...